Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Report from the 18th ECCO- 40th ESMO European Cancer Congress, Vienna 25th–29th September 2015

Report from the 18th ECCO- 40th ESMO European Cancer Congress, Vienna 25th–29th September 2015 special issue ECC2015 Table of Contents 71 Preface 72 News on targeted agents in the advanced setting 75 Interview: “Liquid biopsy is a revolution” 76 Pivotal results and sub-analyses in the field of immunotherapy 79 Interview: “Immunotherapy has opened up a new avenue of research” 80 Lung cancer screening: diagnosis in the nick of time 81 Genomic testing – becoming part of everyday practice 82 Optimising treatment in local and regional lung cancer 83 Small-cell lung cancer: established and novel Lecture Board for this issue: Maximilian Hochmair, MD; Helmut Prosch, MD; approaches Martin Filipits, MD Medical Editor: Dr. Judith Moser other important endpoints, such as Preface quality of life, and define the benefits of new drugs in difficult-to-treat sub- groups. Refined molecular testing tech- Dear Colleagues, niques have become available, although their wide-spread implementation in Oncologists are currently witnessing clinical practice has yet to be improved. rapid diagnostic and therapeutic ad- Significant therapeutic advances vances in their field. These advances were also shown for the immune check- require that physicians are up-to-date point inhibitors nivolumab and pem- regarding the ever-changing standards brolizumab, while new representatives of care. With the present publication, of this drug class, such as atezolizumab, we http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Report from the 18th ECCO- 40th ESMO European Cancer Congress, Vienna 25th–29th September 2015

memo - Magazine of European Medical Oncology , Volume 8 (4) – Dec 15, 2015

Loading next page...
 
/lp/springer-journals/report-from-the-18th-ecco-40th-esmo-european-cancer-congress-vienna-dUKdVpciAx

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2015 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-015-0247-z
Publisher site
See Article on Publisher Site

Abstract

special issue ECC2015 Table of Contents 71 Preface 72 News on targeted agents in the advanced setting 75 Interview: “Liquid biopsy is a revolution” 76 Pivotal results and sub-analyses in the field of immunotherapy 79 Interview: “Immunotherapy has opened up a new avenue of research” 80 Lung cancer screening: diagnosis in the nick of time 81 Genomic testing – becoming part of everyday practice 82 Optimising treatment in local and regional lung cancer 83 Small-cell lung cancer: established and novel Lecture Board for this issue: Maximilian Hochmair, MD; Helmut Prosch, MD; approaches Martin Filipits, MD Medical Editor: Dr. Judith Moser other important endpoints, such as Preface quality of life, and define the benefits of new drugs in difficult-to-treat sub- groups. Refined molecular testing tech- Dear Colleagues, niques have become available, although their wide-spread implementation in Oncologists are currently witnessing clinical practice has yet to be improved. rapid diagnostic and therapeutic ad- Significant therapeutic advances vances in their field. These advances were also shown for the immune check- require that physicians are up-to-date point inhibitors nivolumab and pem- regarding the ever-changing standards brolizumab, while new representatives of care. With the present publication, of this drug class, such as atezolizumab, we

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Dec 15, 2015

There are no references for this article.